Sichuan Kelun-Biotech Completes H Share Full Circulation Conversion

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has completed the full circulation conversion of 8,214,278 domestic and unlisted foreign shares into H shares, representing about 3.52% of its total share capital. The converted H shares will begin trading on the Hong Kong Stock Exchange on April 20, 2026, involving three participating shareholders, including Wealthy Linkage Limited, Future Industry Investment Fund Phase II and Leyue Capital Limited, thereby modestly increasing the company’s freely tradable H share float and enhancing its market liquidity.

This move is expected to strengthen the company’s presence in Hong Kong’s capital market by expanding the portion of shares available to international investors. The completion of the H share full circulation marks a further step in aligning the company’s share structure with market practices for cross-border listed Chinese biopharmaceutical firms, which may improve trading efficiency and broaden its investor base over time.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$526.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company focused on developing and commercializing innovative drug products. The company operates in China’s healthcare and life sciences sector, with its H shares traded on the Hong Kong Stock Exchange, giving it access to international capital markets.

Average Trading Volume: 536,093

Technical Sentiment Signal: Buy

Current Market Cap: HK$121B

For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.